Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer

December 8, 2025 updated by: National Taiwan University Hospital

Impact of Dual Trigger Using Recombinant Human Chorionic Gonadotropin (HCG) and Gonadotropin-releasing Hormone (GnRH) Agonist on Thawed Modified Natural Cycle Outcomes: an Open-label Multi-center Randomized Controlled Trial.

Impact of dual trigger using recombinant human chorionic gonadotropin (HCG) and gonadotropin-releasing hormone (GnRH) agonist on thawed modified natural cycle outcomes: an open-label multi-center randomized controlled trial.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

170

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

1. 24<= Age < 45 patient undergo mNC-FET

Exclusion Criteria:

1. Congenital or acquired uterine abnormalities (uterine malformation, submucosal myoma, intrauterine adhesion or endometrial polyp >1cm)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: dual
GnRH agonist
Drug: GnRH agonist
GnRH agonist add to hcg for trigger
No Intervention: hcg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Implantation
Time Frame: 14 days after embryo transfer
Implantation is defined as a positive serum β-hCG (>20 mIU/mL) measured 14 days after embryo transfer.
14 days after embryo transfer

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical pregnancy
Time Frame: one week after confirm pregnancy
Clinical pregnancy is defined as visualization of a gestational sac on transvaginal ultrasonography one week after pregnancy has been confirmed.
one week after confirm pregnancy
Ongoing pregnancy rate
Time Frame: 5 weeks after confirmed pregnancy
An ongoing pregnancy is defined as a viable intrauterine pregnancy with fetal cardiac activity at ≥9 weeks' gestational age.
5 weeks after confirmed pregnancy
Miscarriage rate
Time Frame: before delivery
before delivery
Gestational age (weeks) at delivery
Time Frame: delivery
Gestational age (weeks) at delivery
delivery
Live birth rate
Time Frame: delivery
delivery
Birth weight
Time Frame: delivery
Birth weight of the bewborn (kg)
delivery
Presence of significant congenital or medical conditions of the newborn
Time Frame: delivery
Presence of significant congenital or medical conditions of the newborn
delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Taiwan University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

September 21, 2025

First Submitted That Met QC Criteria

December 5, 2025

First Posted (Estimated)

December 8, 2025

Study Record Updates

Last Update Posted (Actual)

December 16, 2025

Last Update Submitted That Met QC Criteria

December 8, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 202409081MINB

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Embryo Transfer

Clinical Trials on GnRH agonist

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe